Anti-CDw17(HuLy-m13), 0.2mg/mL

CDw17 / CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19 ) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNF-alpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization. Primary antibodies are available purified, or with a selection of fluorescent CF(R) Dyes and other labels. CF(R) Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF(R)405S and CF(R)405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors. This antibody is available purified with BSA/azide at 200 ug/mL, or BSA/azide-free at 1 mg/mL. Concentration: 0.2 mg/mL Storage buffer: PBS, 0.05% BSA, 0.05% azide